Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of the Response to Therapy With the Combination of Sunitinib and AMG386 in Metastatic Renal Cell Carcinoma.

Trial Profile

Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of the Response to Therapy With the Combination of Sunitinib and AMG386 in Metastatic Renal Cell Carcinoma.

Suspended
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2010

At a glance

  • Drugs Sunitinib; Trebananib
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Nov 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 12 Sep 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 18 Aug 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top